Last $18.10 USD
Change Today -0.30 / -1.63%
Volume 315.6K
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

dynavax technologies corp (DVAX) Snapshot

Open
$18.19
Previous Close
$18.40
Day High
$18.72
Day Low
$17.93
52 Week High
03/5/14 - $20.90
52 Week Low
05/8/14 - $12.50
Market Cap
475.8M
Average Volume 10 Days
404.0K
EPS TTM
$-3.29
Shares Outstanding
26.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYNAVAX TECHNOLOGIES CORP (DVAX)

dynavax technologies corp (DVAX) Related Businessweek News

No Related Businessweek News Found

dynavax technologies corp (DVAX) Details

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

151 Employees
Last Reported Date: 03/10/14
Founded in 1996

dynavax technologies corp (DVAX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $533.3K
Principal Financial Officer, Chief Business O...
Total Annual Compensation: $342.2K
Senior Vice President of Operations and Quali...
Total Annual Compensation: $305.8K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $323.9K
Chief Scientific Officer and Vice President
Total Annual Compensation: $282.6K
Compensation as of Fiscal Year 2013.

dynavax technologies corp (DVAX) Key Developments

Dynavax Technologies Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM

Dynavax Technologies Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Eddie Gray, Chief Executive Officer and Director.

Dynavax Technologies Corporation Enters into Loan and Security Agreement with Hercules Technology Growth Capital, Inc

On December 23, 2014, Dynavax Technologies Corporation entered into a Loan and Security Agreement with Hercules Technology Growth Capital Inc. under which the Company may borrow up to $40.0 million in two tranches. The company borrowed the first tranche of $10.0 million upon closing of the transaction on December 23, 2014. The second tranche, of $30.0 million, can be drawn at the Company's option any time prior to September 30, 2015, but only if the company has achieved certain milestones relating to the ongoing HEPLISAV B Phase 3 study. The company plans to use the proceeds received under the Loan Agreement to provide additional funding for HEPLISAV B development and pre-commercialization activities, as a potential source of funding for clinical trials for its cancer immunotherapeutic product candidate, SD-101, and for general corporate purposes. The interest rate for each tranche will be calculated at a rate equal to the greater of either (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%. Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if the Company achieves Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if the company meets certain additional HEPLISAV-B Phase 3 related milestones on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018. The entire principal balance, including a balloon payment of principal, as applicable, will be due and payable on the Loan Maturity Date. In addition, a final payment equal to $840,000 (if an aggregate of $10.0 million is advanced under the Loan Agreement) or $2,400,000 (if an aggregate of $40.0 million is advanced under the Loan Agreement) will be due on the Loan Maturity Date, or such earlier date specified in the Loan Agreement. The Company's obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property.

Dynavax Technologies Corporation Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Dynavax Technologies Corporation Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $18.10 USD -0.30

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $9.89 USD +1.66
Inovio Pharmaceuticals Inc $8.94 USD +0.06
Peregrine Pharmaceuticals Inc $1.33 USD -0.02
Vical Inc $1.03 USD -0.05
ZIOPHARM Oncology Inc $8.93 USD +0.93
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.7x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.